指南与共识淋巴瘤

原发性皮肤淋巴瘤:ISCL、USCLC与EORTC关于临床试验设计与分期更新的推荐

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
指南 / 共识 · Blood · 2022-01-01

国际皮肤淋巴瘤学会(ISCL)、美国皮肤淋巴瘤联盟(USCLC)与欧洲癌症研究与治疗组织(EORTC)皮肤淋巴瘤工作组联合提出更新版分期及临床试验设计、评估、终点与疗效标准推荐,适用于所有原发性皮肤淋巴瘤,并与Lugano指南对齐。

要点

  • 推荐覆盖所有原发性皮肤淋巴瘤的临床试验设计、评估、终点与疗效标准。
  • 更新分期基于皮肤及结外病变诊断与评估方法的新数据及潜在预后因素。
  • 分期与疗效评估推荐与Lugano指南对齐。

核心结论

  • ISCL、USCLC与EORTC皮肤淋巴瘤工作组提出更新版分期及临床试验设计、评估、终点与疗效标准推荐,适用于所有原发性皮肤淋巴瘤,并与Lugano指南对齐。

研究设计与样本

  • 由国际皮肤淋巴瘤学会(ISCL)、美国皮肤淋巴瘤联盟(USCLC)与欧洲癌症研究与治疗组织(EORTC)皮肤淋巴瘤工作组联合制定推荐。

主要发现

  • 原发性皮肤淋巴瘤相对其他非霍奇金淋巴瘤患者数少而亚型多,除蕈样肉芽肿/Sézary综合征外尚无临床试验指南。
  • 分期基于皮肤及结外病变诊断与评估方法的新数据及潜在预后因素持续更新,并希望与Lugano指南对齐。

关键数值与推荐

  • 推荐覆盖所有原发性皮肤淋巴瘤的临床试验设计、评估、终点与疗效标准,并与Lugano指南对齐。
  • 推荐提供标准化方法学,以促进全球新疗法的规划与监管审批、鼓励研究者发起的合作试验,并有助于评估不同中心和研究间所测药物的比较疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022. PMID: 34758074. doi:10.1182/blood.2021012057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。